Europe Wants Drug Security, but It Won’t Come Cheap
In the winter of 2022, Europe ran short of one of medicine’s workhorses. Amoxicillin — both on its own and in combination with clavulanic acid — became scarce as seasonal demand for pediatric formulations jumped by 500% and manufacturers could not keep pace. “We had shortages throughout the European Union [EU],” said Monica Dias, PharmD, PhD, head of supply and availability of medicines at the European Medicines Agency (EMA).
- ▪In the winter of 2022, Europe ran short of one of medicine’s workhorses.
- ▪Amoxicillin — both on its own and in combination with clavulanic acid — became scarce as seasonal demand for pediatric formulations jumped by 500% and manufacturers could not keep pace.
- ▪“We had shortages throughout the European Union [EU],” said Monica Dias, PharmD, PhD, head of supply and availability of medicines at the European Medicines Agency (EMA).
Opening excerpt (first ~120 words) tap to expand
In the winter of 2022, Europe ran short of one of medicine’s workhorses. Amoxicillin — both on its own and in combination with clavulanic acid — became scarce as seasonal demand for pediatric formulations jumped by 500% and manufacturers could not keep pace. “We had shortages throughout the European Union [EU],” said Monica Dias, PharmD, PhD, head of supply and availability of medicines at the European Medicines Agency (EMA). “We had to ask [the manufacturers] to increase production capacity because we had an increase in demand, and we didn’t have enough supply of these products for European patients.”Monica Dias, PharmD, PhDThe amoxicillin crisis was eventually resolved, but it exposed a deeper fragility.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
